Trends, Patient and Prescriber Characteristics in Gabapentinoid Use in a Sample of United States Ambulatory Care Visits from 2003 to 2016
Kwoh, C Kent
Tighe, Patrick J
Malone, Daniel C
Wilson, Debbie L
Brown, Joshua D
AffiliationUniv Arizona, Coll Pharm, Dept Pharm Practice & Sci
Univ Arizona, Coll Med, Arthrit Ctr
Univ Arizona, Coll Med, Dept Med, Div Rheumatol
Keywordsambulatory care visits
patient and prescriber characteristics
MetadataShow full item record
CitationZhou, L.; Bhattacharjee, S.; Kwoh, C.K.; Tighe, P.J.; Malone, D.C.; Slack, M.; Wilson, D.L.; Brown, J.D.; Lo-Ciganic, W.-H. Trends, Patient and Prescriber Characteristics in Gabapentinoid Use in a Sample of United States Ambulatory Care Visits from 2003 to 2016. J. Clin. Med. 2020, 9, 83.
JournalJOURNAL OF CLINICAL MEDICINE
RightsCopyright © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractIncreasing gabapentinoid use has raised concerns of misuse and abuse in the United States (US). Little is known about the characteristics of gabapentinoid use in general clinical practice over time. This cross-sectional study used data from the National Ambulatory Medical Care Survey. We examined the trends of patient and prescriber characteristics and the diagnoses associated with US ambulatory care visits involving gabapentinoids for adult visits from 2003 to 2016. Using multivariable logistic regression, we estimated the adjusted proportion of gabapentinoid-involved visits among all visits and tested for trend significance. Among the weighted estimate of 260.1 million gabapentinoid-involved visits (aged 18-64 years: 61.8%; female: 61.9%; white: 85.5%), the adjusted annual proportion of gabapentinoid-involved visits nearly quadrupled from 2003 to 2016 (9.1 to 34.9 per 1000 visits; Ptrend < 0.0001), driven mainly by gabapentin. Nearly half had concurrent use with opioids (32.9%) or benzodiazepines (15.3%). Primary care physicians (45.8%), neurologists (8.2%), surgeons (6.2%), and psychiatrists (4.8%) prescribed two-thirds of the gabapentinoids. Most (96.6%) of the gabapentinoid visits did not have an approved indication for gabapentinoids among the first three diagnoses. Among US ambulatory care visits from 2003 to 2016, gabapentinoid use increased substantially, commonly prescribed by primary care physicians.
NoteOpen access journal
VersionFinal published version
- Use of gabapentinoid medications among US adults with cancer, 2005-2015.
- Authors: Fauer AJ, Davis MA, Choi SW, Wallner LP, Friese CR
- Issue date: 2020 Jan
- Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth.
- Authors: McAnally H, Bonnet U, Kaye AD
- Issue date: 2020 Jul 31
- Risk of respiratory depression with opioids and concomitant gabapentinoids.
- Authors: Savelloni J, Gunter H, Lee KC, Hsu C, Yi C, Edmonds KP, Furnish T, Atayee RS
- Issue date: 2017
- Receipt of Substance Use Counseling Among Ambulatory Patients Prescribed Opioids in the United States.
- Authors: Evoy KE, Leonard CE, Covvey JR, Ochs L, Peckham AM, Soprano S, Reveles KR
- Issue date: 2020
- National Ambulatory Medical Care Survey: 2001 summary.
- Authors: Cherry DK, Burt CW, Woodwell DA
- Issue date: 2003 Aug 11